| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 01/29/2003 | EP1119334B1 Two chamber cartridge for atomizers |
| 01/29/2003 | EP1102761B1 Cyclopentabenzofuran derivatives and their use |
| 01/29/2003 | EP1030836B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 01/29/2003 | EP0984966B1 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS |
| 01/29/2003 | EP0572560B1 Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology |
| 01/29/2003 | CN1394201A Substituted glutarimides and use thereof IL-12 production inhibitors |
| 01/29/2003 | CN1393234A 'Jingema' honeyed cream for antipyresis and detoxication |
| 01/29/2003 | CN1393182A Formula and preparing process of beverage for moistening throat |
| 01/29/2003 | CN1099886C Medicine for nasopharyngeal cancer and its preparing process |
| 01/29/2003 | CN1099872C Application of lung surface active matter to pharmaceutical industry |
| 01/28/2003 | WO2002018372A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
| 01/28/2003 | US6511997 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease |
| 01/28/2003 | US6511995 Inhibits collagen synthesis, which is useful for prophylaxis or treatment of fibrosis |
| 01/28/2003 | US6511975 Spiropiperidine derivatives |
| 01/28/2003 | US6511973 Enzyme inhibitors of blood coaggulation factor X for use as anticoaggulants in the treatment of cardiovascular diseases associated with thromboses |
| 01/28/2003 | US6511653 Fluorocarbon polymer coating comprises the monomers tetrafluoroethylene, hexafluoropropylene, perfluoroalkoxyalkylene, and vinylidene fluoride; fluorocarbon propellant |
| 01/28/2003 | US6511652 Fluorocarbon polymer coating comprises the monomers tetrafluoroethylene, hexafluoropropylene, perfluoroalkoxyalkylene, and vinylidene fluoride; fluorocarbon propellant |
| 01/24/2003 | CA2394209A1 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| 01/23/2003 | WO2003006995A2 Method for identifying substances which modulate interleukin 4 (il-4) signaling |
| 01/23/2003 | WO2003006646A1 Regulation of human aminopeptidase n |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006460A1 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006425A2 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006424A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | WO2003006057A1 Composition and method for the treatment of disease |
| 01/23/2003 | WO2003006026A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | WO2003006016A2 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | WO2003006014A1 Medicine comprising combination of five-membered heterocyclic compound and drug compensating for or enhancing its activity |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006003A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | WO2003005999A2 Methods of treating cytokine mediated diseases |
| 01/23/2003 | WO2003005971A2 Tetracycline compounds having target therapeutic activities |
| 01/23/2003 | WO2003005819A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | WO2002072827A9 Traf3-binding b cell-specific receptor |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002047456A3 Urotensin-ii receptor antagonists |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002046138A3 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 01/23/2003 | WO2002040651A3 A human trna-specific adenosine deaminase |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2001098245A3 Triphenyl compounds as interleukin-4 antagonists |
| 01/23/2003 | US20030018194 New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents |
| 01/23/2003 | US20030018180 Secreted protein HFEAF41 |
| 01/23/2003 | US20030018077 Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
| 01/23/2003 | US20030018067 Cardiovascular disorders; anticancer agents |
| 01/23/2003 | US20030018041 Spiroindene and spiroindane compounds |
| 01/23/2003 | US20030018040 Tumor necrosis factor antagonist; side effect reduction;antiinflammatory agents |
| 01/23/2003 | US20030018016 Cell adhesion inhibitors |
| 01/23/2003 | US20030017965 Methods for treating certain diseases using naaladase inhibitors |
| 01/23/2003 | US20030017532 ndp |
| 01/23/2003 | US20030017527 Human vanilloid receptor-like proteins |
| 01/23/2003 | US20030017150 Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses |
| 01/23/2003 | US20030017147 Novel alpha-2-antiplasmin- binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient |
| 01/23/2003 | US20030017145 Treating subjects suffering from herpes virus infections, acquired immunodeficiency syndrome, and hepatitis C infections by administering a compound effective to inhibit the production or release of the ROMs. |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453399A1 Combinations for the treatment of inflammatory disorders |
| 01/23/2003 | CA2453389A1 Aerosol formulations of .delta.8 tetrahydrocannabinol |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453285A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | CA2453147A1 Methods of treating cytokine mediated diseases |
| 01/23/2003 | CA2452491A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 01/23/2003 | CA2451569A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | CA2451566A1 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 01/23/2003 | CA2446726A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | CA2417156A1 3,4-dihydroisoquinoline derivative compound and a pharmaceutical agent comprising it as active ingredient |
| 01/22/2003 | EP1277743A1 Oxa(thia)zolidine derivative and anti-inflammatory drug |
| 01/22/2003 | EP1277467A2 Non-chlorofluorocarbon aerosol formulations |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276853A1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276764A1 Human polynucleotides, polypeptides, and antibodies |
| 01/22/2003 | EP1276760A2 Polyamide nucleic acid derivatives, agents and methods for producing them |
| 01/22/2003 | EP1276755A1 Novel compounds |
| 01/22/2003 | EP1276739A2 Heterocycles that are inhibitors of impdh enzyme |
| 01/22/2003 | EP1276738A1 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors |
| 01/22/2003 | EP1276714A2 Cyclic carboxylic acids as integrin antagonists |
| 01/22/2003 | EP1276502A1 Single-dose antihistamine/decongestant formulations for treating rhinitis |
| 01/22/2003 | EP1276495A1 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases |
| 01/22/2003 | EP1276484A2 Medicine containing polysaccharide substances for activating apoptosis |
| 01/22/2003 | EP1276474A2 Formulations for use in inhaler devices |
| 01/22/2003 | EP1276473A2 Pharmaceutical formulations for dry powder inhalers |
| 01/22/2003 | EP1276472A2 Formulations for use in inhaler devices |
| 01/22/2003 | EP1276467A2 Guaifenesin sustained release formulation and tablets |
| 01/22/2003 | EP1276392A2 Nutritional modules |
| 01/22/2003 | EP1107738A4 Novel pharmaceutical salt form |
| 01/22/2003 | EP1030835B1 Urea derivatives and their use as integrin inhibitors |
| 01/22/2003 | EP0831777B1 Dinucleotides useful for the treatment of lung disease |
| 01/22/2003 | CN1392795A Novel tiotropiumonium-containing inhalation powder |
| 01/22/2003 | CN1391940A Tea and tea mate for nasitic and its preparing method |
| 01/22/2003 | CN1099425C 新的肽衍生物 New peptide derivatives |
| 01/22/2003 | CN1099291C Traditional Chinese medicine preparation for treating nasal meatus disease |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |
| 01/21/2003 | US6509364 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2α antagonists |
| 01/21/2003 | US6509353 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |